There are 108 resources available
ESMO Presidential address
Presenter: Solange Peters
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Webcast
COVID-19: Public health and scientific challenges
Presenter: Anthony Fauci
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Slides
Webcast
How T cells induce cancer regressions
Presenter: Antoni Ribas
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Slides
Webcast
Highlights of the Science weekend
Presenter: John Haanen
Session: ESMO Virtual Congress 2020 Opening ceremony
Resources:
Slides
Webcast
1215O - Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): results from the phase II PRINCEPS trial.
Presenter: Benjamin Besse
Session: Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA84 - Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
Presenter: Solange Peters
Session: Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA38 - Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
Presenter: Yungan Tao
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Slides
Webcast
910O - Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
Presenter: Ezra Cohen
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Slides
Webcast
LBA39 - 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Jean Bourhis
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Slides
Webcast
LBA40 - Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial
Presenter: Lotje Zuur
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Slides
Webcast